DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

Completed · Phase 3 · Has a placebo group

Conditions studied: Hypertension

In brief

This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic and diastolic hypertension despite treatment with full doses of three or more antihypertensive drugs, including a diuretic. Subjects will be randomized to darusentan (optimized dose), an active comparator, or placebo, administered orally. The treatment period for this trial is 14 weeks.

Key facts

Study ID
NCT00389779
Run by
Gilead Sciences
People needed
849
Starts
2006-09-01
Expected to finish
2009-08-01
Last updated by the study team
2014-03-18

Who can join

Age: 35 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.